Kalaris Therapeutics, Inc. - Asset Resilience Ratio
Kalaris Therapeutics, Inc. (KLRS) has an Asset Resilience Ratio of 42.64% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Kalaris Therapeutics, Inc. for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2021)
This chart shows how Kalaris Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. See what is Kalaris Therapeutics, Inc.'s book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Kalaris Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kalaris Therapeutics, Inc. (KLRS) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $34.61 Million | 42.64% |
| Total Liquid Assets | $34.61 Million | 42.64% |
Asset Resilience Insights
- Very High Liquidity: Kalaris Therapeutics, Inc. maintains exceptional liquid asset reserves at 42.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kalaris Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Kalaris Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Kalaris Therapeutics, Inc. (2019–2021)
The table below shows the annual Asset Resilience Ratio data for Kalaris Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 16.21% | $46.46 Million | $286.59 Million | -46.80pp |
| 2020-12-31 | 63.01% | $233.66 Million | $370.82 Million | +16.40pp |
| 2019-12-31 | 46.62% | $64.99 Million | $139.42 Million | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.